Rudolf Maibach
A5049104928- Hepatocellular Carcinoma Treatment and Prognosis
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Pancreatic and Hepatic Oncology Research
- Advanced Breast Cancer Therapies
- Cancer, Hypoxia, and Metabolism
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Liver physiology and pathology
- Prostate Cancer Treatment and Research
- Lymphoma Diagnosis and Treatment
- Ear and Head Tumors
- Prostate Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Gastric Cancer Management and Outcomes
- Liver Disease Diagnosis and Treatment
- Physics and Engineering Research Articles
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Drug-Induced Adverse Reactions
- Testicular diseases and treatments
- Microtubule and mitosis dynamics
- Neuroblastoma Research and Treatments
International Breast Cancer Study Group
2015-2024
Breast International Group
2012-2018
Emma Kinderziekenhuis
2010-2016
Amsterdam UMC Location University of Amsterdam
2016
Gdańsk Medical University
2016
Swiss Group For Clinical Cancer Research
1998-2015
The Coordinating Center
1999-2015
UPMC Hillman Cancer Center
2014
University of Pittsburgh Medical Center
2014
Kantonsspital St. Gallen
2002-2012
Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared tamoxifen, in postmenopausal women hormone-receptor-positive breast cancer.In two phase 3 trials, we randomly assigned premenopausal early cancer to the exemestane plus ovarian suppression or tamoxifen for a period of 5 years. Suppression estrogen production was achieved use gonadotropin-releasing-hormone agonist triptorelin, oophorectomy, irradiation. The primary analysis combined data from 4690 patients...
Suppression of ovarian estrogen production reduces the recurrence hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.We randomly assigned 3066 stratified according prior receipt or nonreceipt chemotherapy, receive 5 years tamoxifen, plus suppression, exemestane suppression. The primary analysis tested hypothesis that suppression would improve disease-free survival, as compared with alone. In analysis, 46.7% patients had...
In the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen Exemestane (TEXT), 5-year rates recurrence breast cancer were significantly lower among premenopausal women who received aromatase inhibitor exemestane plus ovarian suppression than those tamoxifen suppression. The addition to did not result in with alone. Here, we report updated results from two trials.
BackgroundAdjuvant tamoxifen therapy is effective for postmenopausal women with endocrine-responsive breast cancer. Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect efficacy. In this study, we investigated the clinical relevance of polymorphisms.
The primary objective was to determine the efficacy of a newly designed preoperative chemotherapy regimen in an attempt improve cure rate children with high-risk hepatoblastoma.High risk defined as follows: tumor all liver sections (ie, Pretreatment Extension IV [PRETEXT-IV]), or vascular invasion (portal vein [P+], three hepatic veins [V+]), intra-abdominal extrahepatic extension (E+), metastatic disease, alpha-fetoprotein less than 100 ng/mL at diagnosis. Patients were treated alternating...
Preoperative cisplatin alone may be as effective plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level >100 ng per milliliter).Children who were younger than 16 years age eligible for inclusion study. After they received one cycle (80 mg square meter body-surface area 24 hours), we randomly assigned patients to receive (every 14 days) administered preoperative cycles and two postoperative...
Cisplatin chemotherapy and surgery are effective treatments for children with standard-risk hepatoblastoma but may cause considerable irreversible hearing loss. This trial compared cisplatin plus delayed administration of sodium thiosulfate, aiming to reduce the incidence severity cisplatin-related ototoxic effects without jeopardizing overall event-free survival.
This randomized phase II trial evaluated two docetaxel-based regimens to see which would be most promising according overall response rate (ORR) for comparison in a III with epirubicin-cisplatin-fluorouracil (ECF) as first-line advanced gastric cancer therapy.Chemotherapy-naïve patients measurable unresectable and/or metastatic carcinoma, performance status <or= 1, and adequate hematologic, hepatic, renal function randomly received eight 3-weekly cycles of ECF (epirubicin 50 mg/m(2) on day...
ObjectivesIn 2003 the International Breast Cancer Study Group (IBCSG) initiated TEXT and SOFT randomized phase III trials to answer two questions concerning adjuvant treatment for premenopausal women with endocrine-responsive early breast cancer: 1-What is role of aromatase inhibitors (AI) treated ovarian function suppression (OFS)? 2-What OFS who remain are tamoxifen?MethodsTEXT patients receive exemestane or tamoxifen OFS. OFS, alone. Treatment was 5 years from randomization.ResultsTEXT...
The aim of this article is to present an experience two prospective studies from the International Childhood Liver Tumor Strategy Group (SIOPEL 2 [S2] and SIOPEL [S3]) trials evaluate whether modified platinum- doxorubicin-based chemotherapy capable increasing tumor resectability changing patient outcomes.Between 1995 2006, 20 patients with hepatocellular carcinoma (HCC) were included in S2 trial 70 S3 trial. Eighty-five remained evaluable.Response preoperative was observed 29 72 (40%) who...